Estimaciones de analistas de Wall Street para Alaunos Therapeutics, Inc. (TCRT): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 1 |
| Mantener | 8 |
| Venta | 1 |
| Venta fuerte | 0 |
| Analistas totales | 10 |
| Calificación media (1-5) | 0.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-17 | $-15.75 | ||
| 2026-08-14 | $-0.41 | ||
| 2026-05-15 | $-0.59 | ||
| 2026-03-31 | $-0.40 | $-3.69 | +89.1% |
| 2025-11-14 | $-0.55 | $-4.90 | +88.8% |
| 2025-08-14 | $-0.63 | $-5.33 | +88.2% |
| 2025-05-15 | $-0.67 | $-6.44 | +89.6% |
| 2025-03-31 | $-0.46 | $-4.50 | +89.8% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $6.9M | $6.4M | $146000 | 0 | 0 | $398000 | $2.9M | $5000 | $10000 | $5000 |
| Coste de Ventas | 0 | 0 | 0 | $629000 | $1.1M | $47.3M | $22.5M | $4.8M | $362000 | $1.4M |
| Beneficio Bruto | $6.9M | $6.4M | $146000 | -$629000 | -$1.1M | -$46.9M | -$19.6M | -$4.8M | -$352000 | -$1.4M |
| I+D | $157.8M | $45.1M | $34.1M | $38.3M | $52.7M | $49.6M | $25.0M | $16.3M | $362000 | $1.4M |
| Generales y Administrativos | $14.4M | $14.8M | $19.9M | $18.9M | $26.5M | $26.3M | $13.1M | $12.2M | $4.5M | $2.9M |
| Gastos Operativos | $172.2M | $59.9M | $54.1M | $57.2M | $79.2M | $30.7M | $15.5M | $29.5M | $4.5M | $2.9M |
| Beneficio Operativo | -$165.3M | -$53.5M | -$53.9M | -$57.9M | -$80.4M | -$77.5M | -$35.1M | -$34.3M | -$4.8M | -$4.2M |
| EBITDA | -$165.0M | -$53.1M | -$53.3M | -$117.2M | -$78.8M | -$75.0M | -$31.8M | -$30.9M | -$4.7M | -$4.2M |
| Gastos por Intereses | 0 | $830000 | 0 | 0 | 0 | $1.2M | $3.2M | $1.9M | 0 | 0 |
| Beneficio Antes de Impuestos | -$165.3M | -$54.3M | -$53.1M | -$117.8M | -$80.0M | -$78.8M | -$37.7M | -$35.1M | -$4.7M | -$4.2M |
| Impuestos | $114000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$165.3M | -$54.3M | -$53.1M | -$117.8M | -$80.0M | -$78.8M | -$37.7M | -$35.1M | -$4.7M | -$4.2M |
| BPA | $-190.15 | $-59.50 | $-55.52 | $-158.90 | $-56.42 | $-53.80 | $-25.97 | $-21.97 | $-2.92 | $-2.20 |
| BPA Diluido | $-190.15 | $-59.50 | $-55.44 | $-158.90 | $-56.42 | $-53.80 | $-25.97 | $-21.97 | $-2.92 | $-2.20 |
| Acciones en Circulación (Diluidas) | $869276 | $912921 | $956724 | $1.1M | $1.4M | $1.4M | $1.4M | $1.6M | $1.6M | $1.9M |
Precio
| Precio | $1.28 |
| Capitalización | $3M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ADXN · AIM · CYCN · IBO · KTTA · PLRZ · QNRX
Explorar sector: Healthcare · Biotechnology
Más secciones de TCRT: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones